AGP
TVTX icon

Artia Global Partners’s Travere Therapeutics TVTX Stock Holding History

Artia Global Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.1M Hold
70,700
– – 0.42% 37
2025
Q4 		$2.7M Buy
70,700
+39,800
+129% +$1.29M 0.38% 34
2025
Q3 		$739K Hold
30,900
– – 0.12% 46
2025
Q2 		$457K Hold
30,900
– – 0.11% 37
2025
Q1 		$554K Buy
+30,900
New +$627K 0.14% 33

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Artia Global Partners's TVTX Position: Q1 2026 in Review

Artia Global Partners held its Travere Therapeutics (TVTX) position steady in Q1 2026 at 70,700 shares worth $2.1M. The position accounts for 0.42% of the portfolio, ranked #37.

Artia Global Partners first reported a position in TVTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $2.7M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Artia Global Partners held 70,700 shares of Travere Therapeutics worth $2.1M as of Q1 2026.
  • Artia Global Partners left its Travere Therapeutics share count unchanged in Q1 2026.
  • Travere Therapeutics made up 0.42% of Artia Global Partners's portfolio in Q1 2026, its #37 holding.
  • Artia Global Partners first reported a position in Travere Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Artia Global Partners's Travere Therapeutics position peaked at $2.7M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Artia Global Partners's 13F filing for Q1 2026, filed 15 May 2026.